Health

Source link : https://www.newshealth.biz/health-news/hormone-therapy-not-linked-to-sex-based-difference-in-glioma-incidence/ Postmenopausal hormone therapy (HT) did not significantly increase the risk of glioma, leaving unresolved the reason for the sex disparity in incidence, a large retrospective analysis showed. A review of data for 75,335 women produced a nonsignificant 16% increase in the hazard ratio for glioma among women with a history of HT. Analyses of current […] […] More

Source link : https://www.newshealth.biz/health-news/online-sellers-of-compounded-glp-1s-often-dont-mention-risks/ Many online sellers of compounded GLP-1 receptor agonists may be misleading customers, a cross-sectional study suggested. Out of 79 websites that sold a compounded GLP-1 agent, 11 (13.9%) failed to mention the medications were compounded versions and seven (8.9%) wrongfully referred to them as generics, Alissa Chen, MD, MPH, of Yale University School of Medicine […] […] More

Source link : https://www.newshealth.biz/health-news/medpac-members-vote-to-recommend-pay-hikes-for-physicians-and-hospitals/ Physicians would get a 3% Medicare fee-for-service pay increase — with primary care doctors getting a little more and other doctors getting a little less — and hospitals would also receive a pay bump if Congress adopted two draft recommendations approved Thursday by the Medicare Payment Assessment Commission (MedPAC). “I think this reflects really excellent […] […] More

Source link : https://www.newshealth.biz/health-news/iffy-follow-up-care-for-many-patients-with-high-risk-hpv-study-finds/ Less than half of patients who were positive for high-risk human papillomavirus (HPV) with negative cytologic findings were retested during the guideline-recommended time frame, a cohort study showed. During the first 16 months after an index positive HPV result, only 43.7% of patients received an initial surveillance test, of whom 18.2% had HPV-negative results and […] […] More

Source link : https://www.newshealth.biz/health-news/brain-changes-emerge-decades-before-huntingtons-diagnosis/ Cerebrospinal fluid analysis revealed elevated neurofilament light protein and proenkephalin levels 23 years before clinical diagnosis of Huntington’s disease. Brain imaging showed atrophy in the caudate and putamen at this time point. A longitudinal increase in the somatic cytosine-adenine-guanine repeat expansion ratio in blood predicted brain atrophy. Changes in cerebrospinal fluid (CSF) neurofilament light (NfL) […] […] More

Source link : https://www.newshealth.biz/health-news/rheumatologist-accused-of-sex-abuse-by-over-200-patients-is-indicted-on-rape-charges/ A grand jury in Massachusetts has indicted a rheumatologist who is accused of sexually assaulting more than 200 former patients over a period of more than a decade. The patients sued Derrick Todd, MD, who has been accused of performing unnecessary pelvic floor therapy, breast examinations, testicular examinations, and other unwarranted procedures on patients dating […] […] More

Source link : https://health365.info/ai-is-helping-expect-reminiscence-problems-cognitive-decline-throughout-menopausal-transition/ Synthetic intelligence could possibly extra temporarily and cost effectively determine menopausal ladies who’re having issues of reminiscence or cognition. AI successfully recognized ladies with critical subjective cognitive decline (SCD), or self-perceived confusion or reminiscence issues, researchers document in a brand new find out about printed within the magazine Menopause. The use of AI to assist menopausal […] More

Source link : https://www.newshealth.biz/health-news/fda-approves-new-adc-for-hr-her2-breast-cancer/ The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indicated for those who have received prior treatment with endocrine-based therapy and […] […] More

Source link : https://health365.info/learn-about-exhibits-ais-transformative-influence-on-icu-care-with-smarter-predictions-and-clear-insights/ Credit score: Pixabay/CC0 Public Area Extensive care gadgets (ICUs) face mounting drive to successfully arrange sources whilst handing over optimum affected person care. Groundbreaking analysis revealed within the magazine Knowledge Methods Analysis highlights how a unique synthetic intelligence (AI) style is revolutionizing ICU care by way of now not handiest making improvements to predictions of affected […] More

Source link : https://www.newshealth.biz/health-news/fda-approves-datroway-for-pretreated-advanced-breast-cancer/ The FDA approved datopotamab deruxtecan (Datroway) for adults with unresectable or metastatic, hormone receptor (HR)-positive/HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. Efficacy of the Trop2-directed antibody and topoisomerase inhibitor conjugate was evaluated in the multicenter TROPION-Breast01 trial, which included 732 patients randomized to datopotamab deruxtecan or […] […] More

Source link : https://health365.info/pandemic-resulted-in-instant-adoption-of-telemental-fitness-for-the-ones-with-schizophrenia/ For Medicaid beneficiaries with schizophrenia, supply of psychological fitness care via telehealth (telemental fitness care) subtle all of a sudden after onset of the COVID-19 pandemic, in keeping with a find out about printed on-line Jan. 16 in JAMA Community Open. Sharon-Lise Normand, Ph.D., from Harvard Clinical Faculty in Boston, and associates performed a retrospective cohort […] More

Source link : https://www.newshealth.biz/health-news/dont-call-it-cancer-clues-to-exceptional-responses-more-predictions-for-2025/ More debate about whether the lowest-risk prostate cancers should even be called “cancer.” (Harvard Health Publishing) Four cancer drugs — palbociclib (Ibrance), enzalutamide (Xtandi), pomalidomide (Pomalyst), and acalabrutinib (Calquence) — were selected by the Biden administration for the next round of Medicare drug price negotiation. Atara Biotherapeutics acknowledged receipt of a complete response letter from […] […] More